Table 7.
Predictive value of biomarkers for cases of non-follicular-neoplasm-lesion
| CNB samples, no | Matched resected samples, no | Predictive value, % | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Benignity | Malignancy | Total | Sen | Spe | PPV | NPV | AC | ||
| CK19 | Negative | 7 | 3 | 10 | 95.16 | 53.85 | 90.77 | 70.00 | 88.00 |
| Positive | 6 | 59 | 65 | ||||||
| Galectin-3 | Negative | 5 | 3 | 8 | 95.16 | 38.46 | 88.06 | 62.50 | 85.33 |
| Positive | 8 | 59 | 67 | ||||||
| HBME-1 | Negative | 10 | 14 | 24 | 77.42 | 76.92 | 94.12 | 41.67 | 58.00 |
| Positive | 3 | 48 | 51 | ||||||
| CD56 | Positive | 13 | 21 | 34 | 66.13 | 100 | 100 | 38.24 | 72.00 |
| Negative | 0 | 41 | 41 | ||||||
| IHC-COMB1 | Negative | 12 | 7 | 19 | 88.71 | 92.30 | 98.21 | 63.16 | 89.33 |
| Positive | 1 | 55 | 56 | ||||||
| IHC-COMB2 | Negative | 8 | 2 | 10 | 96.77 | 61.54 | 92.31 | 80.00 | 90.67 |
| Positive | 5 | 60 | 65 | ||||||
| IHC-COMB3 | Negative | 2 | 0 | 2 | 100 | 15.38 | 84.93 | 100 | 85.33 |
| Positive | 11 | 62 | 73 | ||||||
| NGS | Negative | 12 | 6 | 18 | 90.32 | 92.31 | 98.25 | 66.67 | 90.67 |
| Positive | 1 | 56 | 57 | ||||||
| IHC-NGS | Negative | 2 | 0 | 2 | 100 | 15.38 | 84.93 | 100 | 85.33 |
| Positive | 11 | 62 | 73 | ||||||
| Total | 13 | 62 | 75 | ||||||
CNB, core needle biopsy; Sen, sensitivity; Spe, specificity; PPV, positive predictive value; NPV, negative predictive value; AC, accuracy; IHC-COMB1, CD56 negative no matter whether CK19, galectin-3, and HBME-1 are positive or not/CD56 positive and all of CK19, galectin-3, and HBME-1 simultaneously positive; IHC-COMB2, CD56 negative no matter whether CK19, galectin-3, and HBME-1 are positive or not/CD56 positive and at least two of CK19, galectin-3, and HBME-1 simultaneously positive; IHC-COMB3, CD56 negative no matter whether CK19, galectin-3, and HBME-1 are positive or not/CD56 positive and at least one of CK19, galectin-3, and HBME-1 simultaneously positive; IHC-NGS, immunohistochemistry and next-generation sequencing combination